A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers

Part of paid clinical trials in Glendale, California.

Sponsor
AstraZeneca
Study ID
NCT06951880
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • AZD4916 — DRUG
    AZD4916 will be administered as oral solution.
  • Placebo — OTHER
    Placebo will be administered as oral solution.

Study Details

The main purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) of AZD4916 in healthy adult participants.

Key Dates

Start date
Jul 23, 2026
Status verified
May 2026
Primary completion
Oct 25, 2027
Completion
Oct 25, 2027

Study Design

Enrollment
160 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: AZD4916
    Parts 1a and 2a participants will receive a single oral dose of AZD4916 on Day 1. Parts 1b and 2b participants will receive a single oral dose of AZD4916 on Day 1 and multiple doses of AZD4916 on Days 4 through 17.
  • Placebo Comparator: Placebo
    Parts 1a and 2a participants will receive a single oral dose of placebo on Day 1. Parts 1b and 2b participants will receive a single dose placebo on Day 1 and multiple doses of placebo on Days 4 through 17.

Primary Outcome Measure

Number of participants with adverse events (AEs) [ Time Frame: From Screening (Day -29 to Day -2) up to 44 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Research SiteGlendaleCalifornia91206-

Find similar trials in Glendale, CA

Related Studies